The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
about
Spontaneous tumor incidence in rasH2 mice: review of internal data and published literature.Accumulation of Mott cells in the spleen in a CB6F1-Tg rasH2 mouse.Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations.Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.Twenty-six-week oral carcinogenicity study of 3-monochloropropane-1,2-diol in CB6F1-rasH2 transgenic mice.Genetically modified laboratory mice with sebaceous glands abnormalities.Identification of biomarkers of chemically induced hepatocarcinogenesis in rasH2 mice by toxicogenomic analysis.Hematopoietic proliferative lesions in the spleen of rasH2 transgenic mice treated with MNU.Animal models for the study of childhood leukemia: considerations for model identification and optimization to identify potential risk factors.Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice.Mutation and overexpression of the transgene in ethylnitrosourea-induced tumors in mice carrying a human prototype c-Ha-ras gene.Effect of oral gavage dosing regimens in female Tg rasH2 transgenic mice.Instability of trinucleotidic repeats during chromatin remodeling in spermatids.Hepatocarcinogenic susceptibility of fenofibrate and its possible mechanism of carcinogenicity in a two-stage hepatocarcinogenesis model of rasH2 mice.The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.Regulatory Forum Opinion Piece: Carcinogen Risk Assessment: The Move from Screens to Science.Investigations of clofibrate in alternative carcinogenicity models.Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration--part I.Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II.A 26-week carcinogenicity study of 2-amino-3-methylimidazo[4,5-f]quinoline in rasH2 mice.Relationship of body weight parameters with the incidence of common spontaneous tumors in Tg.rasH2 mice.Lung Tumor Induction by 26-week Dermal Application of 1,2-Dichloroethane in CB6F1-Tg rasH2 Mice.Medical device regulations and testing for toxicologic pathologists.Reduction in the number of animals and the evaluation period for the positive control group in Tg.rasH2 short-term carcinogenicity studies.Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice.High susceptibility of human c-Ha-ras proto-oncogene transgenic rats to carcinogenesis: a cancer-prone animal model.
P2860
Q34157088-EB6B14B7-0428-40D9-992D-9F7E5EA5577BQ37396936-CA88AE6B-566E-4A65-83C0-6C79F24B195BQ37753534-1E2B6C63-1AA8-4473-A66B-CAAEA0938424Q37795414-A7F769A3-784E-4BEE-AAD0-F88A62CD394AQ38415892-D47C1A31-4B75-4F5B-879D-E46A9043FB3DQ38908417-6A5A2CFC-EE65-4800-961C-3B740E2539C7Q42733623-F7E7FE87-E116-40AB-BC5A-D1C66B6A4F7EQ42872518-18CB6E0A-7CDF-4697-871E-F84B7DAF693FQ44152063-B90688CD-31EE-4CA7-8CEF-5126376EA32CQ44404169-F643748C-B2E2-42BA-9C98-A62E7170228AQ44704085-BD9887AB-E76E-46DB-8A8C-A545507A6A5BQ44942439-7EDDDC2F-A4B9-4DAE-8279-FDA1740B4951Q45301185-60274208-A4DB-4E6F-9380-947B5E0C74DBQ46269041-5EB00693-E8CA-4C9A-A085-310A7C1BBA8BQ46322348-A02F25BF-55DE-494F-9FEF-C92FE390DF94Q46681240-2AF3A7BD-2567-41ED-ACF3-5B5CFA4BFCA0Q46781510-CC4F37F3-F8EF-43A4-86E8-C07ECBC08523Q46781520-0BB4FA62-B67C-4220-8742-1682999CC8F4Q46781523-4E904429-62F5-40A2-BDEE-535A29C9738AQ46781526-BCBCA186-329A-4EF1-ACD1-2FCF56CBB006Q46990423-1181B855-4D3A-469F-B3C5-7411C0652CE4Q47196843-D2F192F1-55AF-45EC-BCCA-E29862DEAD65Q47789678-22CA6B40-7446-4283-9E45-654188A09106Q47849254-5F7C300D-9043-4FFB-A476-7B1C19A6F82AQ48130096-591E47DE-4DD3-4507-8B42-DA05DDE60F8AQ50041581-36D8FDB5-63E0-4204-8262-1D4C61BA0672Q53357105-1B5F9155-ABA1-4D27-A21E-CEEF8F9F96B1
P2860
The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
@ast
The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
@en
The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
@nl
type
label
The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
@ast
The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
@en
The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
@nl
prefLabel
The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
@ast
The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
@en
The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
@nl
P1476
The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
@en
P2093
P356
10.1080/019262301753178492
P407
P478
P577
2001-01-01T00:00:00Z